U.K. watchdogs reject Vertex's CF med Orkambi, citing $147K annual cost

Vertex Pharmaceuticals ($VRTX) is facing a roadblock in the U.K. for its new, pricey cystic fibrosis treatment Orkambi. The country's National Institute for Health and Care Excellence (NICE) recommended against funding the drug, saying that it did not demonstrate enough benefits to patients to justify its high cost. Report

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.